Utilizing novel oncolytic vaccinia virus for selective expression of immunotherapeutic proteins in metastatic tumors

被引：0
|
作者：
Bell, J. [1 ]
Pelin, A. [1 ]
Huh, M. [1 ]
Tang, M. [1 ]
Le Boeuf, F. [1 ]
Keller, B. [1 ]
Duong, J. [1 ]
Clarkknowles, K. [1 ]
Petryk, J. [1 ]
Jennings, V. [2 ]
Melcher, A. [3 ]
Crupi, M. [1 ]
Pikor, L. [1 ]
Caroline, B. [4 ]
Bernstein, S. [4 ]
Burgess, M. [4 ]
机构：
[1] Ottawa Hosp Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada
[2] Univ Leeds, Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England
[3] Inst Canc Res, Translat Immunotherapy, London, England
[4] Turnstone Biol Res & Dev, Ottawa, ON, Canada
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
22LBA (PB-
引用
收藏
页码：E10 / E10
页数：1
相关论文
共 50 条
  • [21] Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum
    Brun, Jan
    Mahoney, Douglas J.
    Le Boeuf, Fabrice
    Lefebvre, Charles
    Sanaei, Cina A.
    Falls, Theresa
    Mccart, J. Andrea
    Stojdl, David F.
    INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (03) : 726 - 731
  • [22] Glycoimmune checkpoint and tumor stroma-targeted oncolytic vaccinia virus for the treatment of solid tumors
    Chan, Winnie M.
    Viskovska, Mariya
    McArthur, Micaela
    Yu, Xue Mary
    Liang, Wei
    Norman, Zane
    Song, Xiaotong
    Chang, Nancy T.
    Jiang, Haiyan
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Development of a tetracycline-inducible system for regulation of oncolytic vaccinia virus gene expression
    Winikoff, S
    Mohammad, S
    Guo, ZS
    O'Malley, M
    Zeh, HJ
    Bartlett, DL
    ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (02) : S124 - S125
  • [24] Phase 2 trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC)
    Kim, S. G.
    Hwang, T. H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S510 - S510
  • [25] Development of a tetracycline-inducible system for regulation of oncolytic vaccinia virus gene expression
    S. Winikoff
    S. Mohammad
    Z. S. Guo
    M. O'Malley
    H. J. Zeh
    D. L. Bartlett
    Annals of Surgical Oncology, 2004, 11 : S124 - S125
  • [26] Phase II trial of pexa-vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC).
    Kim, Seong-Geun
    Ha, Hong Koo
    Lim, Sung-nam
    De Silva, Naomi S.
    Pelusio, Adina
    Mun, Jae Hee
    Patt, Richard H.
    Breitbach, Caroline J.
    Burke, James M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [27] Vaccinia virus injected human tumors: oncolytic virus efficiency predicted by antigen profiling analysis fitted boolean models
    Cecil, Alexander
    Gentschev, Ivaylo
    Adelfinger, Marion
    Dandekar, Thomas
    Szalay, Aladar A.
    BIOENGINEERED, 2019, 10 (01) : 190 - 196
  • [28] Oncolytic vaccinia virus induces a novel phenotype of CD8+ effector T cells characterized by high ICOS expression
    Yamashita, Midori
    Tasaki, Mamoru
    Murakami, Ryuji
    Arai, Yukinori
    Nakamura, Takafumi
    Nakao, Shinsuke
    MOLECULAR THERAPY-ONCOLYTICS, 2021, 20 : 422 - 432
  • [29] Oncolytic vaccinia virus injected intravenously sensitizes pancreatic neuroendocrine tumors and metastases to immune checkpoint blockade
    Inoue, Mitsuko
    Kim, Minah
    Inoue, Tomoyoshi
    Tait, Madeline
    Byrne, Thomas
    Nitschke, Maximilian
    Murer, Patrizia
    Cha, Howard
    Subramanian, Aishwarya
    De Silva, Naomi
    Chiaverotti, Teresa
    McDonald, Donald M.
    MOLECULAR THERAPY-ONCOLYTICS, 2022, 24 : 299 - 318
  • [30] Manipulating TLR pathways activated by oncolytic vaccinia virus elicits a potent immune response against tumors
    Rojas, Juan
    Sampath, Padmavathi
    Hou, Weizhou
    Stephen, Thorne
    JOURNAL OF IMMUNOLOGY, 2014, 192
12345